Background and aims: Right ventricular pacing may lead to heart failure (HF). Upgrades from pacemakers to cardiac resynchronization therapy (CRT) were excluded from most randomized, controlled trials. We sought to determine the long-term outcomes of upgrading from pacemakers to CRT with (CRT-D) or without (CRT-P) defibrillation in patients with no history of sustained ventricular arrhythmias. No group differences emerged in any of these endpoints after propensity score matching. After inverse probability weighting in upgrades, total mortality (HR: 0.55; 95% CI 0.36-0.73), total mortality or HF hospitalization (HR: 0.56; 95% CI 0.34-0.79), and total mortality or hospitalization for MACEs (HR: 0.61; 95% CI 0.40-0.82) were lower after CRT-D than after CRT-P.
INTRODUCTION
Cardiac resynchronization therapy (CRT) is a standard treatment for selected patients with heart failure, impaired left ventricular (LV) function, and a wide QRS complex. 1 Most randomized, controlled trials of CRT have excluded patients with previously implanted devices and, therefore, the randomized, controlled evidence base for CRT is limited to de novo CRT. Up to 27% of patients attending a typical pacemaker clinic have heart failure (HF). 2 Right ventricular (RV) pacing is life-saving in patients with brady-
arrhythmia, but it induces a pattern of ventricular activation akin to
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. a left bundle branch block. This causes (LV) mechanical dyssynchrony, which is now known to precipitate HF. The first clinical evidence for a detrimental effect of RV pacing emerged from randomized trials comparing the effects of atrial versus RV pacing in patients with sick sinus syndrome, in which up to 40% of patients developed HF with RV pacing. 3, 4 In the Dual Chamber and VVI Implantable Defibrillator (DAVID) study 5, 6 and the Mode Selection Trial (MOST), 7 RV pacing was also associated with a higher risk of HF hospitalization.
Several studies have explored the acute and short-term effects of upgrading from RV pacing to CRT. [8] [9] [10] [11] [12] [13] We, as others, have shown that the symptomatic response 12, 14 and outcomes 15 of upgrading to CRT are similar to de novo CRT. The 2012 ACCF/AHA/HRS (American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines/the Heart Rhythm Society) guideline 16 recommended a CRT upgrade at generator replacement if LV function is severely impaired and the expected pacing requirement is ≥40%. 17 An observational study of patients with implanted pacemakers or implantable cardioverter defibrillators (ICDs) upgraded to either CRTpacemaker (CRT-P) or CRT-defibrillator (CRT-D) 18 provided the evidence base for the 2016 European Society of Cardiology guideline recommendation to offer CRT upgrade to patients with HF. While upgrading was adopted in clinical practice even before such recommendations emerged, 19, 20 the clinical question remains as to whether CRT-D should be used in preference to CRT-P at the time of upgrading patients with pacemakers and without prior ventricular arrhythmias.
In the present study, we have compared long-term outcomes of CRT-D and CRT-D, implanted either de novo or as an upgrade from pacemakers over a period of 16 years.
METHODS
The study population consisted of patients undergoing a successful CRT device implantation for in the period from October 2000 to January 2016 at two centers (Queen Elizabeth Hospital and Good Hope Hospital, Birmingham, United Kingdom). Patients with a previous ICD implant or a sustained ventricular arrhythmia warranting upgrade to CRT-D were excluded. Some patients (n = 394) were included in a previous study. 15 The present study increases the number of patients and the length of follow-up. 
Device therapy
Device implantation was undertaken using standard transvenous techniques under local anesthesia and intravenous sedation. After implantation, patients were followed-up in dedicated device therapy clinics. Device optimization using transmitral Doppler-directed optimization of atrioventricular delay using an iterative technique was undertaken up to 2013, when routine echocardiographic optimization F I G U R E 1 Primary and secondary endpoints in de novo implants and upgrades. Kaplan-Meier survival curves for clinical outcomes according whether patients had a de novo implant or an upgrade. CRT-D = cardiac resynchronization therapy-defibrillation; CRT-P = cardiac resynchronization therapy-pacing; HF = heart failure; MACE = major adverse cardiovascular events [Color figure can be viewed at wileyonlinelibrary.com] was no longer deemed necessary on the basis of emerging evidence.
Thereafter, optimization was only undertaken in symptomatic nonresponders. In patients in sinus rhythm, backup atrial pacing was set at 60 beats/min, and the pacing mode was set to DDDR with an interventricular delay of 0-20 ms (LV stimulation first). In patients with permanent atrial fibrillation, RV and LV leads were implanted and a CRT generator was used, plugging the atrial port and programming to a either VVIR or ventricular triggered modes, according to physician's discretion. Atrioventricular junction ablation was undertaken according to physicians' discretion. Note: Variables are expressed as mean ± SD, unless indicated otherwise. * refers to differences between the groups from ANOVA for continuous variables and from 2 tests for categorical variables. † includes permanent, persistent, and paroxysmal atrial fibrillation (AF). ACEIs = angiotensin-converting enzyme inhibitors; ARAs = angiotensin receptor blockers; CABG = coronary artery bypass grafting; CRT-D = cardiac resynchronization therapy-defibrillation; CRT-P = cardiac resynchronization therapy-pacing; ECG = electrocardiogram; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonists; NYHA = New York Heart Association.
TA B L E 1 Baseline characteristics

Endpoints
The primary endpoint was total mortality, which included cardiac transplantation or implantation of a ventricular assist device. Secondary endpoints included: the composite endpoint of total mortality or HF hospitalization, and the composite endpoint of total mortality or unplanned hospitalization for major adverse cardiac events (MACEs), which included hospitalization for HF, myocardial infarction, acute coronary syndrome, and arrhythmia (ventricular tachycardia, ventricular fibrillation, and atrial fibrillation). Stroke and pulmonary embolism were not considered as MACEs. In composite endpoints, the first event was used for censoring. Mortality data were collected through medical records and from interviews with patients' caregivers. Clinical events were collected every 6 months from the start of the study in 2000 by investigators who had access to patient clinical records, but no access to previously collected patient data or device-related data, which are kept separate from clinical records. Events were adjudicated by investigators at arbitrary intervals of 6 months using hospital records and death certificates. Note: This shows the results of propensity score matching for de novo implants and upgrades. Note that the populations are well matched. Abbreviations as in Table 1 .
TA B L E 2 Event rates
TA B L E 4
Propensity score matching and inverse probability weighting in upgrades to CRT-D versus upgrades to CRT-P Note: Results from propensity score matching and inverse probability weighting in upgraded patients, comparing CRT-D versus CRT-P. Results are expressed as hazard ratios (HR) and 95% confidence intervals (CI). HF = heart failture. Other abbreviations as in Table 1 .
Statistical analysis
Continuous variables are expressed as mean ± standard deviation. Normality was tested using the Shapiro-Wilk test. Comparisons between normally distributed continuous variables were made using analysis of variance, and categorical variables were analyzed using 2 tests. Kaplan-Meier curves and the log-rank test were used to assess observed cumulative survival. Cox proportional hazard models were used to assess relative risks. Proportionality hypotheses were verified F I G U R E 2 Primary and secondary endpoints in propensity-matched samples. Kaplan-Meier survival curves for clinical outcomes according whether patients had a de novo implant or an upgrade. CI = confidence interval; CRT-D = cardiac resynchronization therapy-defibrillation; CRT-P = cardiac resynchronization therapy-pacing; HF = heart failure; MACE = major adverse cardiovascular events; psm HR = propensity score-matched hazard ratio [Color figure can be viewed at wileyonlinelibrary.com]
by visual examination of log (survival) graphs to ensure parallel slopes, and by examining Schoenfeld residuals. Variables with a P < 0.10 on univariable analyses were entered in multivariate models, and further backward elimination was applied for the final multivariate models.
Statistical analyses were performed using Stata 14 (StataCorp, College
Station, TX, USA). A two-tailed P-value of < 0.05 was considered statistically significant.
Propensity matching was undertaken for comparisons of de novo
and for upgrades. Variables were selected if they differed significantly at baseline and if they emerged as predictors of total mortality. A 1:1 nearest-neighbor matching procedure within a caliper width of 0.01 was used. Each pair was used once and unpaired cases were excluded.
The standardized difference was used to assess the balance between upgrades and de novo groups, and a difference of <10% was accepted for matched cohorts. 22 After matching, proportional hazards regression was used to compare survival outcomes in both groups. In the comparison between CRT-D and CRT-P upgrades, an inverse probability weighting approach was used, using all patients upgraded to CRT as reference.
RESULTS
Baseline characteristics in de novo implants and upgrades
Of 1,349 patients scheduled for de novo device implantation, a suc- As shown in Table 1 , the de novo and upgrade groups were well matched for sex, New York Heart Association (NYHA) class, comorbidities, and uptake of loop diuretics and beta-blockers. Upgraded patients were on average 4 years older (P < 0.001) and were more likely to have atrial fibrillation (P < 0.001) and to receive CRT-P (P < 0.001). They had a higher LV ejection fraction (LVEF, P < 0.001) and were less likely to have ischemic cardiomyopathy (P = 0.024) and to have received angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARAs) (P = 0.002) and mineralocorticoid receptor antagonists (MRAs) (P = 0.001).
Outcomes in de novo versus upgrade implants
Total mortality was 664/1,314 (50.5%; 12. 2.0-5.7] for upgrades) ( Table 2 ). In Kaplan-Meier survival analyses CI 0.81-1.33) were comparable (HRs are for upgrades compared to de novo implants). Multivariate Cox proportional hazards analyses also showed no differences in these endpoints (see Online Appendix). Similar findings emerged in analyses of propensity score-matched samples ( Figure 2 ). As shown in subgroup analyses (Figure 3 ), total mortality after upgrades compared to de novo implants was significantly higher in men, NYHA class III, CRT-P, nonischemic cardiomyopathy, nondiabetic status, left bundle branch block, a QRS ≥ 150 ms, and a LVEF ≤ 25%.
Baseline characteristics according to device upgrade type
Of the 231 upgraded patients, 61 (26.4%) were upgraded to primary prevention CRT-D and 170 (73.6%) to CRT-P. As shown in Table 1 , the groups were well matched for sex, comorbidities, atrial rhythm, QRS duration and morphology, LVEF, and uptake of ACEIs/ARAs and MRAs. Compared to CRT-P upgrade patients, CRT-D upgrade patients were 4.9 years younger (P < 0.001), had a better NYHA class (86.4%
and 90.4% in NYHA class III or IV, respectively; P = 0.008), and were more likely to have ischemic cardiomyopathy (P = 0.001). In addition, CRT-D upgrade patients had a higher uptake of beta-blockers (P = 0.002).
Outcomes according to device upgrade type
In Kaplan-Meier survival analyses (Figure 3 ), CRT-D upgrades had a lower total mortality (P = 0.002), total mortality or HF hospitalization (P = 0.001), and total mortality or hospitalization for MACEs (P < 0.001). We undertook a two-step procedure to correct variable imbalance. First, we undertook propensity score matching between de novo implants and upgrades (Table 3) , using the variables either differed significantly at baseline or that emerged as predictors of primary endpoint, among which age emerged as a significant predictor. Second, we undertook both inverse probability weighting and propensity score matching between CRT-D and CRTP upgrades in order to correct for age and other variables (Table 4) . After inverse probability weighting after CRT-D than after CRT-P (all P < 0.001). The findings of multivariate Cox proportional hazards analyses and inverse probability weighting were similar. Cardiac mortality was lower in CRT-D upgrades (logrank P = 0.005), but no differences in noncardiac mortality emerged (log-rank P = 0.139) ( Figure 5 ). 
DISCUSSION
This is the largest study with the longest follow-up of patients undergoing upgrading from pacemakers to CRT-D or CRT-P in the context of primary prevention, i.e., patients with no history of sustained ventricular arrhythmias before the initial pacemaker implant or the CRT upgrade procedure. We found that, after covariate adjustment, the risk of total mortality, total mortality or HF hospitalization, and total mortality or hospitalization for MACEs was similar in upgraded patients compared to patients undergoing de novo CRT implantation. Moreover, outcomes were consistently better after an upgrade to CRT-D rather than to CRT-P.
De novo implants versus upgrades
Vamos et al. recently compared 375 de novo CRT-D implants and 177
CRT-D upgrade procedures. 23 Over a mean follow-up of 3.1 years, upgrades were associated with a higher mortality. Importantly, however, the patient population included upgrades from ICD to CRT-D and a large proportion of patients (42%) were upgraded to CRT-D for secondary prevention, compared to only 11.1% in the de novo group.
Therefore, this study does not address upgrades in the context of primary prevention, but a heterogeneous population with a preexisting arrhythmic risk. In contrast, we found that after propensity score matching of "primary prevention" patients, outcomes were comparable after de novo implants and upgrades.
CRT-D versus CRT-P upgrade
An argument for upgrading to CRT-P is that LV dysfunction in patients with pacemakers is likely to be due to RV pacing and that CRT should are upgraded to CRT may not derive any significant benefit from the addition of a defibrillator. 24 In contrast, we found that CRT-D upgrade was consistently superior to CRT-P upgrades with respect to the three main endpoints, even after inverse probability weighting. In addition, analysis of cause of death showed that this was predominantly due to a lower cardiac rather than noncardiac death. Our findings have emerged in the context of the ongoing BUDAPEST CRT trial, 25 which will compare upgrading from pacemakers to ICD or CRT-D, but not from pacemakers to CRT-P or CRT-D. Currently, there are no planned trials addressing whether CRT-D is superior to CRT-P at the time of upgrading from pacemakers in the context of primary prevention.
Limitations
This is nonrandomized and observational study and, therefore, our findings should be interpreted with caution. The groups were significantly unbalanced. In particular, there was a specific bias toward CRT-P in nonischemic cardiomyopathy and CRT-D in ischemic cardiomyopathy. This is a known bias. As this study was not randomized, there will also be multiple unknown biases which may influence survival and other outcomes. Unfortunately, LV function was not systematically coded prior to implantation of conventional pacemakers. Given that some patients underwent the original pacemaker implantation before the advent of CRT, it is possible that, in contrast to our current practice, a proportion may not have had an echocardiogram. Some patients may have had LV dysfunction and/or HF at the time of pacemaker implantation. In addition, the serial uptake of RV pacing was not systematically collected and reduction of RV pacing was not systematically attempted, as this study precedes the development of appropriate algorithms. In addition, programming and changes thereof throughout the follow-up period, which were not systematically addressed, could also impact on outcomes. The lack of systematic collection of therapies (antitachycardia pacing and shocks) delivered is further limitation.
CONCLUSIONS
We have found that in patients with HF and preexisting pacemakers, upgrading to CRT is associated with a similar long-term risk of mortality and HF hospitalization to patients undergoing de novo CRT. In upgraded patients, CRT-D was associated with lower mortality than CRT-P.
